GlassScriptPhysician profile
Vicente A Diaz
NPI 1114190154
$18,223.82
in general payments reported to CMS, 2019-2025
16 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Uveitis and Ocular Inflammatory Disease provider received nationally (typical 2025 total: $471).
See the full distribution for Uveitis and Ocular Inflammatory Disease
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2021: $297 · 2022: $3,617 · 2023: $13K · 2024: $429 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K · Food and Beverage: $1,422 · Travel and Lodging: $739 · Education: $87.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,500.00 |
| Food and Beverage | $1,421.51 |
| Travel and Lodging | $738.61 |
| Education | $87.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $16,455.88 | 2022-2024 | Miebo, Xipere, Xiidra |
| Johnson & Johnson Surgical Vision, INC. | $488.00 | 2019-2022 | |
| Harrow Eye, LLC | $295.49 | 2024-2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $237.61 | 2021-2025 | Acthar |
| Celularity INC. | $183.57 | 2021 | |
| Astellas Pharma US INC | $125.00 | 2023 | Izervay |
| Abbvie INC. | $114.41 | 2022-2023 | Durysta |
| Rxsight INC | $93.28 | 2023 | Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens |
| Allergan, INC. | $76.19 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $34.85 | 2021 | |
| Ani Pharmaceuticals, INC. | $25.05 | 2022 | |
| Aerie Pharmaceuticals, INC. | $23.53 | 2019 | |
| Mallinckrodt Enterprises LLC | $18.98 | 2019 | |
| Sun Pharmaceutical Industries INC. | $18.55 | 2019 | |
| Kala Pharmaceuticals, INC. | $16.77 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $16.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicente Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.